Clinical Trials

81 enrolled

Breast Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

372 enrolled

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05340413 2026-03-16

RADIOLA

65 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

60 enrolled

Breast Neoplasms

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

14 enrolled 8 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05203445 2026-01-12

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

23 enrolled

Breast Neoplasms

NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

BreastClassical hematology

114 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT06201234 2025-12-01

ELEMENT

176 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

119 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498155 2025-06-10

OlympiaN

50 enrolled

Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

BreastClassical hematology

23 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05033756 2024-05-07

COMPRENDO

11 enrolled

Breast Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

BreastClassical hematology

54 enrolled 17 charts

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT05629429 2024-01-17

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Phase 2 Unknown

300 enrolled

Breast Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

99 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03367689 2023-02-22

NOBROLA

Phase 2 Terminated

7 enrolled

Breast Neoplasms

NCT02681562 2016-02-15

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Phase 2 Unknown

45 enrolled